SCHEMBL892668

SCHEMBL892668

CC[Si](CC)(CC)c1[nH]c2ccc(C(F)(F)F)cc2c1CCO

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
KIF11 P52732 4/20 0.46
CHUK O15111 1/20 0.41
EGFR P00533 2/20 0.41
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.38
TSHR P16473 1/20 0.38
HTT P42858 1/20 0.38
CDK2 P24941 1/20 0.37
DRD2 P14416 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
MAPK1 P28482 1/20 0.36
MAP2K4 P45985 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30532272 1.00 CYP2C9 (0.47) CYP2C9CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL7679735 0.87 KIF11 (0.46) CYP2C9CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL891994 0.87 KIF11 (0.46) MEN1KMT2AKIF11CHUKEGFR
SCHEMBL4951539 0.84 HTT (0.40) MEN1KMT2AKIF11CHUKKDM4E
SCHEMBL18932887 0.82 ALDH1A1 (0.44) MEN1KMT2AKIF11EGFRKDM4E
SCHEMBL15313180 0.82 KIF11 (0.43) MEN1KMT2AKIF11CHUKEGFR
SCHEMBL892954 0.78 MEN1 (0.53) CYP2C9MEN1KMT2ACHUKALDH1A1
SCHEMBL3925023 0.78 MAP4K1 (0.34) CYP2C9CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL7698333 0.77 ALDH1A1 (0.43) MEN1KMT2AKIF11KDM4EALDH1A1
SCHEMBL14499883 0.72 GHSR (0.43) MEN1KMT2AKIF11CHUKKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4406957-B1 ARYL RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME NOGRA PHARMA LTD (IE) 2026-04-08 EP disclosed
US-12577256-B2 Aryl receptor modulators and methods of making and using the same NOGRA PHARMA LIMITED (IE) 2026-03-17 US disclosed
US-20250066384-A1 ARYL RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME NOGRA PHARMA LIMITED (IE) 2025-02-27 US disclosed
EP-4406957-A2 ARYL RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME Nogra Pharma Limited (IE) 2024-07-31 EP disclosed
US-12012418-B2 Aryl receptor modulators and methods of making and using the same NOGRA PHARMA LIMITED (IE) 2024-06-18 US disclosed
EP-3160964-B1 ARYL RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME NOGRA PHARMA LTD (IE) 2024-03-13 EP disclosed
CN-116947880-A Aryl receptor modulators and methods of making and using the same 诺格拉制药有限公司 2023-10-27 CN disclosed
CN-111978319-B Aryl receptor modulators and methods of making and using the same 诺格拉制药有限公司 2023-08-11 CN disclosed
US-20230234963-A1 ARYL RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME NOGRA PHARMA LIMITED (IE) 2023-07-27 US disclosed
US-11427600-B2 Aryl receptor modulators and methods of making and using the same NOGRA PHARMA LIMITED (IE) 2022-08-30 US disclosed
EP-2651887-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES Katholieke Universiteit Leuven K.U. Leuven R&D (BE) 2013-10-23 EP disclosed
EP-2651888-A1 NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES Katholieke Universiteit Leuven K.U. Leuven R&D (BE) 2013-10-23 EP disclosed
US-20130274260-A1 NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND (BE) 2013-10-17 US disclosed
CN-103261156-A New compounds for the treatment of neurodegenerative diseases LEUVEN K U RES & DEV 2013-08-21 CN disclosed
CN-102803252-A Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases UNIV LEUVEN KATH 2012-11-28 CN disclosed
WO-2012080220-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2012-06-21 WO disclosed
WO-2012080221-A1 NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2012-06-21 WO disclosed
EP-2440550-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) 2012-04-18 EP disclosed
US-20120083475-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2012-04-05 US disclosed
WO-2010142801-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577256-B2 Aryl receptor modulators and methods of making and using the same AHR, IL23R, ARNT CYP2C9 486/4885CYP1A2 192/4885CYP3A4 697/4885
US-20120083475-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, MAPT, NLN CYP2C9 4482/4885CYP1A2 3183/4885CYP3A4 3828/4885
US-20250066384-A1 ARYL RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME AHR, IFNAR1, IL23R CYP2C9 272/4885CYP1A2 85/4885CYP3A4 210/4885
US-20130274260-A1 NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, MAPT, PSEN1 CYP2C9 4382/4885CYP1A2 3641/4885CYP3A4 3772/4885
US-12012418-B2 Aryl receptor modulators and methods of making and using the same AHR, IL23R, IL2RA CYP2C9 311/4885CYP1A2 69/4885CYP3A4 213/4885
US-11427600-B2 Aryl receptor modulators and methods of making and using the same AHR, IL23R, IL2RA CYP2C9 311/4885CYP1A2 69/4885CYP3A4 213/4885
US-20230234963-A1 ARYL RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME AHR, IL23R, IL2RA CYP2C9 311/4885CYP1A2 69/4885CYP3A4 213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.